IMAIL MSSM EDU TRIAL

People in this group will receive combination chemotherapy intravenously (oxaliplatin, leucovorin calcium, and fluorouracil) on day 1, then continuously over 46 hours on days 1-3.Treatment repeats every 14 days for up to 25 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV starting on day 1 of cycle 1 or 2.Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. People in this group will receive combination chemotherapy intravenously (oxaliplatin, leucovorin calcium and fluorouracil) on day 1, then continuously over 46 hours on days 1-3.People will be assigned randomly to one of two groups: All participating patients will know which of the two groups they have been assigned to and which treatments they are being given. The study is randomized participants will be placed into one of the two study groups by chance.The other group will receive combination chemotherapy alone. There will be two treatment groups in this study. One group will receive combination chemotherapy along with the drug atezolizumab.The study is an open-label, 2-arm, randomized study. This study is focused on patients who have a biomarker known as MSI-High or dMMR, which are commonly seen in people with Lynch syndrome. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment with combination chemotherapy agents alone.

IMAIL MSSM EDU TRIAL

This phase III trial is for people with stage 3 colon cancer. Immunotherapy may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Imail mssm edu